BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 1606543)

  • 21. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study.
    Maese L; Loh ML; Choi MR; Lin T; Aoki E; Zanette M; Agarwal S; Iannone R; Silverman JA; Silverman LB; Raetz EA; Rau RE
    Blood; 2023 Feb; 141(7):704-712. PubMed ID: 36108304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attenuation of asparaginase-induced hyperglycemia after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation.
    Ridgway D; Neerhout RC; Bleyer A
    Cancer; 1989 Feb; 63(3):561-3. PubMed ID: 2643458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing asparaginase therapy for acute lymphoblastic leukemia.
    Rizzari C; Conter V; Starý J; Colombini A; Moericke A; Schrappe M
    Curr Opin Oncol; 2013 Mar; 25 Suppl 1():S1-9. PubMed ID: 23380829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia.
    Woo MH; Hak LJ; Storm MC; Sandlund JT; Ribeiro RC; Rivera GK; Rubnitz JE; Harrison PL; Wang B; Evans WE; Pui CH; Relling MV
    J Clin Oncol; 2000 Apr; 18(7):1525-32. PubMed ID: 10735901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative pharmacokinetic studies of three asparaginase preparations.
    Asselin BL; Whitin JC; Coppola DJ; Rupp IP; Sallan SE; Cohen HJ
    J Clin Oncol; 1993 Sep; 11(9):1780-6. PubMed ID: 8355045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
    Mondelaers V; Ferster A; Uyttebroeck A; Brichard B; van der Werff Ten Bosch J; Norga K; Francotte N; Piette C; Vandemeulebroecke K; Verbeke C; Schmidt S; Benoit Y; Lammens T; De Moerloose B
    Br J Haematol; 2020 Jul; 190(1):105-114. PubMed ID: 32057100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia.
    Castaman G; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):57-60. PubMed ID: 8039761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan.
    Ogawa C; Taguchi F; Goto H; Koh K; Tomizawa D; Ohara A; Manabe A
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28244643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allergic Reactions With Intravenous Compared With Intramuscular Pegaspargase in Children With High-risk Acute Lymphoblastic Leukemia: A Population-based Study From the Maritimes, Canada.
    MacDonald T; Kulkarni K; Bernstein M; Fernandez CV
    J Pediatr Hematol Oncol; 2016 Jul; 38(5):341-4. PubMed ID: 26925715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase.
    Fernandez CA; Stewart E; Panetta JC; Wilkinson MR; Morrison AR; Finkelman FD; Sandlund JT; Pui CH; Jeha S; Relling MV; Campbell PK
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1307-13. PubMed ID: 24771103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of hypersensitivity reactions between intravenous and intramuscular applications of native
    Odaman Al I; Özdemir N; Zengin Ersoy G; Bayram C; Vupa Çilengiroğlu Ö; Arslantaş E; Paslı Uysalol E; Ayçiçek A
    J Oncol Pharm Pract; 2023 Sep; 29(6):1454-1460. PubMed ID: 36942380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group.
    Brigitha LJ; Fiocco M; Pieters R; Albertsen BK; Escherich G; Lopez-Lopez E; Mondelaers V; Vora A; Vrooman L; Schmiegelow K; van der Sluis IM;
    Eur J Cancer; 2022 Feb; 162():65-75. PubMed ID: 34954438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
    Ebeid EN; Kamel MM; Ali BA
    J Egypt Natl Canc Inst; 2008 Jun; 20(2):127-33. PubMed ID: 20029468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences.
    Burke MJ; Zalewska-Szewczyk B
    Future Oncol; 2022 Mar; 18(10):1285-1299. PubMed ID: 35107320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Allergic complications of L-asparaginase therapy in children with acute lymphoblastic leukaemia].
    Konstantinidis N; Kolarović J; Kaćanski N; Vijatov-Djurić G; Konstantinidis G
    Srp Arh Celok Lek; 2011; 139(11-12):749-52. PubMed ID: 22338470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
    Mall V; Thomas KB; Sauter S; Niemeyer CM; Sutor AH
    Klin Padiatr; 1999; 211(4):205-10. PubMed ID: 10472551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study.
    Risseeuw-Appel IM; Dekker I; Hop WC; Hählen K
    Med Pediatr Oncol; 1994; 23(4):335-43. PubMed ID: 8058004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.
    Duval M; Suciu S; Ferster A; Rialland X; Nelken B; Lutz P; Benoit Y; Robert A; Manel AM; Vilmer E; Otten J; Philippe N
    Blood; 2002 Apr; 99(8):2734-9. PubMed ID: 11929760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A desensitization protocol in children with L-asparaginase hypersensitivity.
    Akbayram S; Doğan M; Akgün C; Caksen H; Oner AF
    J Pediatr Hematol Oncol; 2010 Jul; 32(5):e187-91. PubMed ID: 20505537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erwinia asparaginase in pediatric acute lymphoblastic leukemia.
    Salzer W; Seibel N; Smith M
    Expert Opin Biol Ther; 2012 Oct; 12(10):1407-14. PubMed ID: 22946493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.